Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.58 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 6/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | HTR3A | P46098 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | GPR4 | P46093 | 1/20 | 0.44 |
| ▸ | EP300 | Q09472 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6136145 | 0.94 | ESR1 (0.56) | ESR1ESR2PRKCZKDM1ASLC6A2 | |
| SCHEMBL6136074 | 0.90 | ESR1 (0.61) | ESR1ESR2CHEK2 | |
| SCHEMBL6135904 | 0.89 | ESR1 (0.60) | ESR1ESR2CHEK2 | |
| SCHEMBL6136133 | 0.89 | ESR1 (0.57) | ESR1ESR2PRKCZKDM1ASLC6A2 | |
| SCHEMBL6135908 | 0.89 | ESR1 (0.59) | ESR1ESR2SLC6A4 | |
| SCHEMBL6135921 | 0.87 | ESR1 (0.59) | ESR1ESR2PRKCZSLC6A2SLC6A4 | |
| SCHEMBL6135970 | 0.86 | ESR1 (0.58) | ESR1ESR2PRKCZSLC6A2SLC6A4 | |
| SCHEMBL6136203 | 0.85 | ESR1 (0.59) | ESR1ESR2PRKCZ | |
| SCHEMBL6136015 | 0.85 | ESR1 (0.57) | ESR1ESR2PRKCZSLC6A2SLC6A4 | |
| SCHEMBL6135993 | 0.84 | ESR1 (0.58) | ESR1ESR2PRKCZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0895989-B1 | 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity | LILLY CO ELI (US) | 2005-05-18 | — | — | EP | claimed |
| WO-1999007377-A1 | 1-[4-(SUBSTITUTED ALKOXY)BENZYL]NAPHTHALENE COMPOUNDS HAVING ESTROGEN INHIBITORY ACTIVITY | ELI LILLY AND COMPANY (US) | 1999-02-18 | — | — | WO | claimed |
| EP-0895989-A1 | 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity | ELI LILLY AND COMPANY (US) | 1999-02-10 | — | — | EP | claimed |
| EP-0895989-B1 | 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity | LILLY CO ELI (US) | 2005-05-18 | — | — | EP | disclosed |
| US-6509356-B1 | Estrogen inhibitory activity method for the treatment of breast cancer in a woman comprising administering to a patient a therapeutically effective amount of a compound | ELI LILLY AND COMPANY | 2003-01-21 | — | — | US | disclosed |
| WO-1999007377-A1 | 1-[4-(SUBSTITUTED ALKOXY)BENZYL]NAPHTHALENE COMPOUNDS HAVING ESTROGEN INHIBITORY ACTIVITY | ELI LILLY AND COMPANY (US) | 1999-02-18 | — | — | WO | disclosed |
| EP-0895989-A1 | 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity | ELI LILLY AND COMPANY (US) | 1999-02-10 | — | — | EP | disclosed |